Evidence map›Paper›PMID 31584115›Full record

ArticleMedical molecular morphology2020

An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells.

Noriko Hiramatsu, Naoki Yamamoto, Sumito Isogai, Takanori Onouchi, Masaya Hirayama, Shingo Maeda, Takuma Ina, Masashi Kondo, Kazuyoshi Imaizumi

Abstract read
PubMed Publisher
In one paragraph

Article in Medical molecular morphology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Cellular models in autoinflammatory disease research.Clinical & translational immunology · 2024
    Review
  3. Feasibility of repairing skin defects by VEGFJournal of cellular and molecular medicine · 2023
    Article
  4. Progress on methods of T lymphocyte developmentZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Noriko HiramatsuCenter for Joint Research Facilities Support, Fujita Health University Research Promotion and Support Headquarters, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Naoki YamamotoCenter for Joint Research Facilities Support, Fujita Health University Research Promotion and Support Headquarters, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. naokiy@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0002-9659-3204
Sumito IsogaiDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Takanori OnouchiCenter for Joint Research Facilities Support, Fujita Health University Research Promotion and Support Headquarters, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Masaya HirayamaCenter for Joint Research Facilities Support, Fujita Health University Research Promotion and Support Headquarters, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Shingo MaedaDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Takuma InaDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Masashi KondoDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Kazuyoshi ImaizumiDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Fujita Health University · JPFujita Health University Hospital · JP

Funding

Japan Society for the Promotion of Science 17K09677Japan Society for the Promotion of Science 17K11495Japan Society for the Promotion of Science 18K15935
6 · The paper itself

Abstract

Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.

Indexed as

Cell DifferentiationCells, CulturedChemokine CCL17CX3C Chemokine Receptor 1Dendritic CellsFemaleFlow CytometryHealthy VolunteersHLA-DR AntigensHumansImmunotherapyInduced Pluripotent Stem CellsLipopolysaccharide ReceptorsMaleMiddle AgedMonocytesCCL17 protein, humanCD14 protein, humanChemokine CCL17CX3C Chemokine Receptor 1CX3CR1 protein, humanHLA-DR AntigensLipopolysaccharide ReceptorsDendritic cellsDifferentiationHLA-DRHuman peripheral monocyteMonocyte-derived iPS cellsPhagocytosis

Identifiers

PMID31584115
OpenAlexW2978551982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.